GlassScriptPhysician profile
Jeffrey T Guptill
NPI 1548439383
$101,890.42
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $29K · 2021: $28K · 2022: $3,578.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78,744.69 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $5,043.75 | 2020 | |
| Grifols USA, LLC | $4,626.98 | 2020 | |
| Ucb, INC. | $3,025.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $2,947.50 | 2022 | |
| Janssen Research & Development, LLC | $2,200.00 | 2021 | |
| Janssen Global Services, LLC | $1,620.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,600.00 | 2021 | |
| Becton, Dickinson and Company | $945.00 | 2021-2022 | |
| Ucb Sa | $825.00 | 2020 | |
| Bio Products Laboratory USA, INC. | $312.50 | 2019 |
5 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Guptill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.